Methods and compositions for norovirus vaccines and diagnostics
AssigneeThe University of North Carolina at Chapel Hill
InventorsLisa Chon Lindesmith, Ralph Steven Baric, Kari Moore Debbink, Eric Francis Donaldson
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods and compositions for norovirus therapeutics, such as vaccines, and diagnostics.
Claims19
A chimeric norovirus capsid protein consisting of a norovirus VP1 major capsid protein backbone from norovirus strain GII.4.1974 (SEQ ID NO:1), norovirus strain GII.4.1987 (SEQ ID NO:2), norovirus strain GII.4.1997 (SEQ ID NO:3), norovirus strain GII.4.2002 (SEQ ID NO:4), norovirus strain GII.4.2002a (SEQ ID NO:5), norovirus strain GII.4.2004 (SEQ ID NO:6), norovirus strain GII.4.2005 (SEQ ID NO:7), norovirus strain GII.4.2006 (SEQ ID NO:8), norovirus strain GII.4.2007 (SEQ ID NO:9), norovirus strain GII.4.2008a (SEQ ID NO:10), norovirus strain GII.4.2008s (SEQ ID NO:11), norovirus strain GII.4.2009 (SEQ ID NO:12), or norovirus strain GII.4.2012 (SEQ ID NO:13) in which two or more, in any combination, of the following sets of amino acid residues (a)-(k):
- a) amino acid residues 294, 296, 297, 298, 368 and 372 (Epitope A);
- b) amino acid residues 333 and 382 (Epitope B);
- c) amino acid residues 340 and 376 (Epitope C);
- d) amino acid residues 391, 393, 394, 395 and 396 (Epitope D);
- e) amino acid residues 407, 412 and 413 (Epitope E);
- f) amino acid residues 234, 310, 316, 484 and 493 (Epitope F);
- and
- g) amino acid residues 327 and 404 (Epitope Fs),
- wherein amino acid residue numbering of (a)-(g) is based on the amino acid sequence of any of SEQ ID NOs:4-13;
- and
- h) amino acid residues 391, 393, 394 and 395 (Epitope D);
- i) amino acid residues 406, 411 and 412 (Epitope E);
- j) amino acid residues 234, 310, 316, 483 and 492 (Epitope F), and
- k) amino acid residues 327 and 403 (Epitope Fs),
- wherein amino acid residue numbering of (h)-(k) is based on the amino acid sequence of SEQ ID NOs:1-3,
- are substituted into the capsid protein backbone to introduce at least one epitope from each of two or more different norovirus strains of the above norovirus strains, each of which is different from one another and each of which is different from the norovirus strain of the capsid protein backbone.
A chimeric norovirus capsid protein consisting of a norovirus VP1 major capsid protein backbone from norovirus strain GII.4.1974 (SEQ ID NO:1), norovirus strain GII.4.1987 (SEQ ID NO:2), norovirus strain GII.4.1997 (SEQ ID NO:3), norovirus strain GII.4.2002 (SEQ ID NO:4), norovirus strain GII.4.2002a (SEQ ID NO:5), norovirus strain GII.4.2004 (SEQ ID NO:6), norovirus strain GII.4.2005 (SEQ ID NO:7), norovirus strain GII.4.2006 (SEQ ID NO:8), norovirus strain GII.4.2007 (SEQ ID NO:9), norovirus strain GII.4.2008a (SEQ ID NO:10), norovirus strain GII.4.2008s (SEQ ID NO:11), norovirus strain GII.4.2009 (SEQ ID NO:12), or norovirus strain GII.4.2012 (SEQ ID NO:13) in which amino acid residues 234, 310, 316, 484 and 493 (Epitope F), wherein amino acid residue numbering is based on the amino acid sequence of any of SEQ ID NOs:4-13 or amino acid residues 234, 310, 316, 483 and 492 (Epitope F), wherein amino acid residue numbering is based on the amino acid sequence of any of SEQ ID NOs:2, 3 or 1, are substituted into the capsid protein backbone to introduce Epitope F from a norovirus strain that is different from the norovirus strain of the capsid protein backbone.
4-10. (canceled)
A chimeric norovirus capsid protein consisting of a norovirus VP1 major capsid protein backbone from norovirus strain GII.3 (SEQ ID NO:14), in which one or more, in any combination, of the following sets of amino acid residues (a)-(k) are substituted into the norovirus capsid protein backbone from norovirus strain GII.3 to introduce one or more epitope in any combination, from one or more different norovirus strains having an amino acid sequence of SEQ ID Nos:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13, in any combination, as follows:
- a) amino acid residues 294, 296, 297, 298, 368 and 372 (Epitope A) substituted at positions 294, 310, 311, 312, 381 and 384, respectively, in the amino acid sequence of SEQ ID NO:14;
- b) amino acid residues 333 and 382 (Epitope B) substituted at positions 347 and 394, respectively, in the amino acid sequence of SEQ ID NO:14;
- c) amino acid residues 340 and 376 (Epitope C) substituted at positions 353 and 388, respectively, in the amino acid sequence of SEQ ID NO:14;
- d) amino acid residues 391, 393, 394 and 395 (Epitope D) substituted at positions 403, 404, 405 and 406, respectively, in the amino acid sequence of SEQ ID NO:14;
- e) amino acid residues 407, 412 and 413 (Epitope E) substituted at positions 415, 420 and 421, respectively, in the amino acid sequence of SEQ ID NO:14;
- f) amino acid residues 234, 310, 316, 484 and 493 (Epitope F) substituted at positions 234, 324, 330, 492 and 501, respectively, in the amino acid sequence of SEQ ID NO:14;
- and
- g) amino acid residues 327 and 404 (Epitope Fs) substituted at positions 341 and 412, respectively, in the amino acid sequence of SEQ ID NO:14,
- wherein amino acid residue numbering of (a)-(g) is based on the amino acid sequence of any of SEQ ID NOs:4-13;
- and
- h) amino acid residues 391, 393, 394 and 395 (Epitope D) substituted at positions 403, 404, 405 and 406, respectively, in the amino acid sequence of SEQ ID NO:14;
- i) amino acid residues 406, 411 and 412 (Epitope E) substituted at positions 415, 420 and 421, respectively, in the amino acid sequence of SEQ ID NO:14;
- j) amino acid residues 234, 310, 316, 483 and 492 (Epitope F) substituted at positions 234, 324, 330, 492 and 501, respectively, in the amino acid sequence of SEQ ID NO:14, and
- k) amino acid residues 327 and 403 (Epitope Fs) substituted at positions 341 and 412, respectively, in the amino acid sequence of SEQ ID NO:14,
- wherein amino acid residue numbering of (h)-(k) is based on the amino acid sequence of SEQ ID NOs:1-3.
(canceled)
Dependencies are inferred from the claim text.